These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 20351977)

  • 21. [Becaplermin gel (Regranex gel)].
    Senet P
    Ann Dermatol Venereol; 2004 Apr; 131(4):351-8. PubMed ID: 15258509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of chronic non-healing ulcers using autologous platelet rich plasma: a case series.
    Suthar M; Gupta S; Bukhari S; Ponemone V
    J Biomed Sci; 2017 Feb; 24(1):16. PubMed ID: 28241824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical safety of becaplermin (rhPDGF-BB) gel. Becaplermin Studies Group.
    Smiell JM
    Am J Surg; 1998 Aug; 176(2A Suppl):68S-73S. PubMed ID: 9777975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical trial report stirs debate.
    Magee G; Ovington LG
    Adv Skin Wound Care; 2006 Mar; 19(2):64; author reply 64, 67. PubMed ID: 16557046
    [No Abstract]   [Full Text] [Related]  

  • 25. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.
    Sibbald RG; Torrance G; Hux M; Attard C; Milkovich N
    Ostomy Wound Manage; 2003 Nov; 49(11):76-84. PubMed ID: 14652415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autologous Platelet-Rich Plasma for Diabetic Foot Ulcer.
    Shao S; Pan R; Chen Y
    Trends Endocrinol Metab; 2020 Dec; 31(12):885-890. PubMed ID: 33199085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential effects of platelet-derived growth factor BB in accelerating wound healing in aged versus young animals: the impact of tissue hypoxia.
    Wu L; Brucker M; Gruskin E; Roth SI; Mustoe TA
    Plast Reconstr Surg; 1997 Mar; 99(3):815-22; discussion 823-4. PubMed ID: 9047202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical protocol: Phase I trial to evaluate the safety of H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer.
    Margolis DJ; Crombleholme T; Herlyn M
    Wound Repair Regen; 2000; 8(6):480-93. PubMed ID: 11208175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunomodulatory role of Tinospora cordifolia as an adjuvant in surgical treatment of diabetic foot ulcers: a prospective randomized controlled study.
    Purandare H; Supe A
    Indian J Med Sci; 2007 Jun; 61(6):347-55. PubMed ID: 17558098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The nitric oxide connection: hyperbaric oxygen therapy, becaplermin, and diabetic ulcer management.
    Boykin JV
    Adv Skin Wound Care; 2000; 13(4 Pt 1):169-74. PubMed ID: 11075012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Experimental research on the effects of different activators on the formation of platelet-rich gel and the release of bioactive substances in human platelet-rich plasma].
    Yang Y; Zhang W; Cheng B
    Zhonghua Shao Shang Za Zhi; 2017 Jan; 33(1):12-17. PubMed ID: 28103989
    [No Abstract]   [Full Text] [Related]  

  • 32. Human plasma fibronectin potentiates the mitogenic activity of platelet-derived growth factor and complements its wound healing effects.
    Larivière B; Rouleau M; Picard S; Beaulieu AD
    Wound Repair Regen; 2003; 11(1):79-89. PubMed ID: 12581430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Effectiveness and Safety of Platelet-Rich Plasma for Chronic Wounds: A Systematic Review and Meta-analysis.
    Qu W; Wang Z; Hunt C; Morrow AS; Urtecho M; Amin M; Shah S; Hasan B; Abd-Rabu R; Ashmore Z; Kubrova E; Prokop LJ; Murad MH
    Mayo Clin Proc; 2021 Sep; 96(9):2407-2417. PubMed ID: 34226023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries.
    Ghatnekar O; Persson U; Willis M; Odegaard K
    Pharmacoeconomics; 2001; 19(7):767-78. PubMed ID: 11548912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical study of local injection of autologous platelet-rich plasma in treatment of diabetic foot ulcer].
    Qin X; Wang J
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2019 Dec; 33(12):1547-1551. PubMed ID: 31823556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of chronic ulcers in the lower extremities with topical becaplermin gel .01%: a multicenter open-label study.
    Guzman-Gardearzabal E; Leyva-Bohorquez G; Salas-Colín S; Paz-Janeiro JL; Alvarado-Ruiz R; García-Salazar R
    Adv Ther; 2000; 17(4):184-9. PubMed ID: 11185057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study.
    Rees RS; Robson MC; Smiell JM; Perry BH
    Wound Repair Regen; 1999; 7(3):141-7. PubMed ID: 10417749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [New developments in the treatment of diabetic foot ulcers].
    Bakker K; Schaper NC
    Ned Tijdschr Geneeskd; 2000 Feb; 144(9):409-12. PubMed ID: 10719543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of becaplermin (rhPDGF-BB) gel for chronic nonhealing ulcers. A retrospective analysis.
    Mandracchia VJ; Sanders SM; Frerichs JA
    Clin Podiatr Med Surg; 2001 Jan; 18(1):189-209, viii. PubMed ID: 11344978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Which is the better option: recombinant human PDGF-BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off-loaded by a customized contact cast?
    Bhansali A; Venkatesh S; Dutta P; Dhillon MS; Das S; Agrawal A
    Diabetes Res Clin Pract; 2009 Jan; 83(1):e13-6. PubMed ID: 19081156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.